Update on Diagnosis and Treatment of PA - Prof. Dr. Paolo Mulatero (Torino, Italy)

As first stage of our Tour Académique 2024, Prof. Dr. Paolo Mulatero explains current strategies for diagnosing and treating Primary Aldosteronism (PA).

Dr. Paolo Mulatero is Professor of Internal Medicine and Head of the Hypertension Unit, Department of Medical Sciences at the University of Torino, Italy. His main research interests include pathophysiology; clinical and molecular genetics of primary aldosteronism; biochemistry and genetics of 11b-hydroxylase and aldosterone synthase (CYP11B1 and CYP11B2) and their role in human pathologies (essential hypertension, primary aldosteronism, glucocorticoid-remediable aldosteronism, aldosterone synthase deficiency type I and II); clinical genetics of the monogenic forms of hypertension; the genetic and pathophysiology of essential and secondary hypertension and the evaluation of the cardiovascular risk factors.

The interview was recorded on May 22th, 2024.

Moderators: Prof. Dr. Dominique Guerrot (Rouen, France), Prof. Dr. Marcus Säemann (Vienna, Austria), and Prof. Dr. Gunnar Heine (both Frankfurt, Germany).

Articles discussed:

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.
Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, Foster D, Huang SA, Rhyee S, Sweetser MT, Bakris GL.
N Engl J Med 2023
doi: 10.1056/NEJMoa2208391

Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism.
Burrello J, Buffolo F, Domenig O, Tetti M, Pecori A, Monticone S, Poglitsch M, Mulatero P.
Hypertension 2020
doi: 10.1161/HYPERTENSIONAHA.119.13772

Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism.
Satoh F, Ito S, Itoh H, Rakugi H, Shibata H, Ichihara A, Omura M, Takahashi K, Okuda Y, Iijima S.
Hypertens Res 2021
doi: 10.1038/s41440-020-00570-5

Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism.
Yoshida Y, Fujiwara M, Kinoshita M, Sada K, Miyamoto S, Ozeki Y, Iwamoto M, Mori Y, Nagai S, Matsuda N, Noguchi T, Okamoto M, Gotoh K, Masaki T, Shibata H.
Hypertens Res 2024
doi: 10.1038/s41440-023-01412-w

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators.
Eur Heart J. 2022 Feb 10;43(6):474-484. doi: 10.1093/eurheartj/ehab777